Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2023 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
February 23, 2023 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board

LONDON and NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease...
February 21, 2023 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.

LONDON and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company...
December 30, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease...
December 22, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in...
December 21, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO to Participate at Biotech Showcase

LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
December 06, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
December 01, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited - Change of Auditor

LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
November 24, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Limited – PDMR dealing

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
November 21, 2022 02:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease

-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- LONDON and BOSTON, Nov. 21, 2022 (GLOBE...